Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

OGT to Launch New Cancer Focused CytoSure™ Array at CCMC Meeting

Published: Tuesday, July 30, 2013
Last Updated: Tuesday, July 30, 2013
Bookmark and Share
Reliable CCMC-standardised array for CNV and LOH detection in haematological malignancies and solid tumours.

Oxford Gene Technology (OGT) will launch its new CytoSure™ Consortium Cancer +SNP array (4x180k) at the Cancer Cytogenomics Microarray Consortium (CCMC) and Cytogenomics Array Group (CAGdb) combined meeting in Chicago on the 5th- 7th August, booth 4.

The new CytoSure™ Consortium Cancer +SNP array allows the simultaneous detection of copy number variation (CNV) and loss of heterozygosity (LOH), with a SNP resolution that enables reporting of LOH at 10Mb. Focusing on content recommended by the CCMC, an international organisation of clinical cytogeneticists, molecular cytogeneticists and molecular pathologists, this targeted array covers over 500 cancer genes and 130 cancer-associated genomic regions for haematological malignancies and solid tumours. The CCMC-approved standardised array design is intended to improve clinical research quality and promotes collaboration and communication between cancer cytogenomics laboratories.

The new array will be the latest addition to a range of OGT microarrays specifically designed for detecting CNV and LOH on a single array for cancer research. This includes the recently released CytoSure Cancer +SNP array (4x180k) covering 1500 cancer associated genes and the CytoSure Haematological Cancer + SNP array (8x60k) focused specifically on haematological cancers. Due to the unique design of OGT’s SNP probes, there are no changes to the standard aCGH protocol, no restriction digest is required and any reference sample can be used. This enables the use of matched samples which is a particular advantage in cancer research, allowing constitutional abnormalities to be filtered out. For effortless data analysis, OGT’s CytoSure Interpret Software is supplied with all CytoSure arrays and delivers reliable and user-friendly data analysis, providing rapid access to meaningful results.

James Clough, Executive Vice President Commercial at OGT, said: “The new CytoSure Consortium Cancer +SNP array is part of OGT’s commitment to advancing the field of cytogenetic cancer research. OGT’s collaborations in the design and development of our arrays with international organisations such as the CCMC who are leaders in cancer cytogenetics research, are testament to this. By providing reliable, high-quality CNV and SNP detection for haematological malignancies and solid cancers, these arrays are valuable tools for accurately and efficiently defining the genetic nature of cancers, advancing research into novel and improved therapeutics”.

Delegates of the CCMC / CAGdb meeting can find out more about OGT’s expertise in cancer cytogenetics by attending a talk by Ephrem Chin, Regional Sales manager at OGT, entitled ‘Oxford Gene Technology – Meeting laboratory needs’. The talk will be presented as part of the ‘Data quality and QC metrics’ workshop at 1 – 3pm on the 6th August and provides an opportunity for researchers to share in OGT’s extensive experience in high-throughput array processing and associated QC metrics and data analysis.

OGT representatives will also be available at booth 4 for the duration of the meeting.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Oversubscribed OGT Workshop at ESHG 2012 Now Available Online
Experts discuss the use of arrays and NGS to identify causative mutations in cancer.
Thursday, July 19, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT’s miRNA Profiling Service Provides Answers for Disease Research
Company has designed the microRNA profiling service designed to help researchers accelerate their discoveries.
Friday, May 16, 2008
Scientific News
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Imaging Software Could Speed Up Breast Cancer Diagnosis
Researchers use high speed optical microscopy of intact breast tissue specimens to analyze breast tissue.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Synthetic DNA Vaccine Against MERS Shows Promise
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species.
How Small RNA Helps Form Memories
In a new study, a team of scientists at Scripps Florida has found that a type of genetic material called "microRNA" (miRNA) plays surprisingly different roles in the formation of memory in animal models.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!